New Leaf Venture Partners L.l.c. buys $5,790,507 stake in Dermira Inc (DERM)

Dermira Inc (DERM) : New Leaf Venture Partners L.l.c. scooped up 6,862 additional shares in Dermira Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 183,884 shares of Dermira Inc which is valued at $5,790,507.Dermira Inc makes up approximately 4.72% of New Leaf Venture Partners L.l.c.’s portfolio.

Other Hedge Funds, Including , Schwab Charles Investment Management Inc boosted its stake in DERM in the latest quarter, The investment management firm added 14,566 additional shares and now holds a total of 62,986 shares of Dermira Inc which is valued at $1,983,429.Aisling Capital reduced its stake in DERM by selling 868,230 shares or 89.43% in the most recent quarter. The Hedge Fund company now holds 102,593 shares of DERM which is valued at $3,230,654. Dermira Inc makes up approx 0.69% of Aisling Capital’s portfolio.Timessquare Capital Management boosted its stake in DERM in the latest quarter, The investment management firm added 1,101,645 additional shares and now holds a total of 2,491,526 shares of Dermira Inc which is valued at $78,458,154. Dermira Inc makes up approx 0.50% of Timessquare Capital Management’s portfolio.Blackrock Institutional Trust Company N.a. boosted its stake in DERM in the latest quarter, The investment management firm added 164,589 additional shares and now holds a total of 464,369 shares of Dermira Inc which is valued at $14,622,980.Monashee Investment Management boosted its stake in DERM in the latest quarter, The investment management firm added 100,000 additional shares and now holds a total of 125,965 shares of Dermira Inc which is valued at $4,189,596. Dermira Inc makes up approx 6.41% of Monashee Investment Management’s portfolio.

Dermira Inc opened for trading at $30.94 and hit $32.26 on the upside on Thursday, eventually ending the session at $32.22, with a gain of 3.80% or 1.18 points. The heightened volatility saw the trading volume jump to 1,97,402 shares. Company has a market cap of $1,140 M.

Many Wall Street Analysts have commented on Dermira Inc. Company shares were Reiterated by Wedbush on Jun 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .Company shares were Reiterated by Needham on Jun 2, 2016 to “Buy”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .

Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.

Leave a Reply

Dermira Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Dermira Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.